Company profile for TuHURA Biosciences

TuHURA Biosciences

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

pharmacompass-1-m-2025-12-22

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

Contact Supplier

pharmacompass-2-m-2025-11-03

Contact Supplier

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

14 News #PharmaBuzz

media
14 News #PharmaBuzz

DEVELOPMENTS

13 Drugs in Development

13 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

TuHURA Biosciences is a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy. Its lead candidate, IFx-2.0, is designed to enhance the efficacy of checkpoint inhibitors and is set for a Phase 3 trial with Keytruda® in advanced Merkel Cell Carcinoma. Additionally, TuHURA is developing first-in-class bi-specific ADCs and PDCs targeting Myeloid Derived Suppressor Cells to prevent T cell exhaust...

TuHURA Biosciences is a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy. Its lead candidate, IFx-2.0, is designed to enhance the efficacy of checkpoint inhibitors and is set for a Phase 3 trial with Keytruda® in advanced Merkel Cell Carcinoma. Additionally, TuHURA is developing first-in-class bi-specific ADCs and PDCs targeting Myeloid Derived Suppressor Cells to prevent T cell exhaustion and acquired resistance, advancing novel therapies to improve patient outcomes in cancer treatment.

Tides AsiaTides Asia

Not Confirmed

Not Confirmed

24-26 February, 2026

Tokyo, Japan
BIO Partnering at JPMBIO Partnering at JPM

Not Confirmed

Not Confirmed

12-15 January, 2026

San Francisco Marriott Marquis, California
Biotech ShowcaseBiotech Showcase

Not Confirmed

Not Confirmed

12-14 January, 2026

San Diego, California, U.S.A

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

United_States_of_America Flag

Country

Country

U.S.A

Address

Address

10500 University Center Drive Suite 110 Tampa FL 33612

Telephone

Telephone

Email

enquiries@pharmacompass.com

Client Website

Website

https://tuhurabio.com/

Linkedin

https://www.linkedin.com/company/tuhurabio/

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Tuhura Biosciences Targets (DOR) To Reprogram MDSCs at ASH

03 Nov 2025

// PR NEWSWIRE

TuHURA Biosciences to Speak at 27th HC Wainwright Conference

20 Aug 2025

// PR NEWSWIRE

TuHura Biosciences Reports Q2 2025 Financials, Corporate Update

14 Aug 2025

// PR NEWSWIRE

TuHURA Biosciences Joins Russell 3000 and Russell 2000 Indexes

01 Jul 2025

// PR NEWSWIRE

TuHURA Biosciences Completes Acquisition of Kineta

30 Jun 2025

// PR NEWSWIRE

TuHURA Biosciences Begins Phase 3 Trial of IFx-2.0 with Keytruda®

24 Jun 2025

// PR NEWSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search